Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Mornex

Showing results (361-370 of 374) with videos related to

Pageof 38
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 17, 2016
T Cells Promote Bronchial Epithelial Cell Secretion of Matrix Metalloproteinase-9 via a C-C Chemokine Receptor Type 2 Pathway: Implications for Chronic Lung Allograft DysfunctionM Pain, P-J Royer, J Loy, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2004
Induction treatment before surgery for non-small cell lung cancerW E Eberhardt, K S Albain, H Pass, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)S Peters, U Dafni, M Boyer, et al.
Gastroenterologie Clinique Et Biologique|July 23, 1999
[What can be done for digestive cancer in 1999? Recommendations of the French Foundation of Digestive Cancer (1st Part)]J C Barbare, L Bedenne, O Bouché, et al.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
Gastroenterologie Clinique Et Biologique|August 3, 1999
[What can be done for patients with digestive cancer in 1999? Guidelines of the French Foundation of Digestive Cancerology (2nd part)]J C Barbare, L Bedenne, O Bouché, et al.
ESMO Open|June 4, 2024
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-RA R Filippi, J Bar, C Chouaid, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|October 27, 2018
[Siriade 2.0: An e-learning platform for radiation oncology contouring]J-E Bibault, F Denis, A Roué, et al.
Orphanet Journal of Rare Diseases|May 26, 2020
Lung function in Birt-Hogg-Dubé syndrome: a retrospective analysis of 96 patientsC Daccord, V Cottin, G Prévot, et al.
Revue Des Maladies Respiratoires|August 14, 2018
[COLT: Ten years of research in lung transplantation, results and perspectives]A Tissot, A Foureau, C Brosseau, et al.
Pageof 38

Showing results (361-370 of 374) with videos related to

Sort By:
Pageof 38
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 17, 2016
T Cells Promote Bronchial Epithelial Cell Secretion of Matrix Metalloproteinase-9 via a C-C Chemokine Receptor Type 2 Pathway: Implications for Chronic Lung Allograft DysfunctionM Pain, P-J Royer, J Loy, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2004
Induction treatment before surgery for non-small cell lung cancerW E Eberhardt, K S Albain, H Pass, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)S Peters, U Dafni, M Boyer, et al.
Gastroenterologie Clinique Et Biologique|July 23, 1999
[What can be done for digestive cancer in 1999? Recommendations of the French Foundation of Digestive Cancer (1st Part)]J C Barbare, L Bedenne, O Bouché, et al.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
Gastroenterologie Clinique Et Biologique|August 3, 1999
[What can be done for patients with digestive cancer in 1999? Guidelines of the French Foundation of Digestive Cancerology (2nd part)]J C Barbare, L Bedenne, O Bouché, et al.
ESMO Open|June 4, 2024
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-RA R Filippi, J Bar, C Chouaid, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|October 27, 2018
[Siriade 2.0: An e-learning platform for radiation oncology contouring]J-E Bibault, F Denis, A Roué, et al.
Orphanet Journal of Rare Diseases|May 26, 2020
Lung function in Birt-Hogg-Dubé syndrome: a retrospective analysis of 96 patientsC Daccord, V Cottin, G Prévot, et al.
Revue Des Maladies Respiratoires|August 14, 2018
[COLT: Ten years of research in lung transplantation, results and perspectives]A Tissot, A Foureau, C Brosseau, et al.
Pageof 38